{"disease":{"id":"portal-vein-tumour-thrombosis","name":"portal vein tumour thrombosis"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06960954","title":"PIVKA-II for Predicting Portal Vein Thrombosis in Hepatocellular Carcinoma","phase":"","overall_status":"RECRUITING","enrollment_count":116,"lead_sponsor_name":"Tanta University","has_results":false},{"nct_id":"NCT05137899","title":"Neoadjuvant Combination of Atezolizumab/Bevacizumab Versus Neoadjuvant Radiation Therapy","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":1,"lead_sponsor_name":"Ontario Clinical Oncology Group (OCOG)","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}